参考文献/References:
[1]李克敏,宋亮,尹如铁.2017年第4版NCCN卵巢癌临床实践指南解读[J].华西医学,2018(4):398-402.
[2]Colombo N,Sessa C,du Bois A,et al.ESMO-ESGO consensus conference recommendations on ovarian cancer:pathology and molecular biology, early and advanced stages, borderline tumors and recurrent disease[J].Ann Oncol,2019,30(5):672-705.
[3]Kurman RJ,Carcangiu ML,Herrington CS,et al.WHO classification of tumors of female reproductive organs[J]. Lyon:International Agency for Research on Cancer,2014.
[4]Lu TP,Kuo KT,Chen CH,et al.Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model[J].Cancers,2019,11(2):E270.
[5]初桂伟,赵月,田春燕,等.上皮性卵巢癌术后复发影响因素分析[J].解放军医药杂志,2019(1):30-32.
[6]Huang L,Xu AM.SET and MYND domain containing protein 3 in cancer[J].American Journal of Translational Research,2017,9(1):1-14.
[7]Giakountis A,Moulos P,Sarris ME,et al.Smyd3-associated regulatory pathways in cancer[J].Seminars in Cancer Biology,2017(42):70-80.
[8]Tsai CH,Chen YJ,Yu CJ,et al.SMYD3-Mediated H2A.Z.1 Methylation Promotes Cell Cycle and Cancer Proliferation[J].Cancer Research,2016,76(20):6043-6053.
[9]Liu TT,Xu H,Gao WP,et al.SET and MYND Domain-Containing Protein 3 (SMYD3) Polymorphism as a Risk Factor for Susceptibility and Poor Prognosis in Ovarian Cancer[J].Med Sci Monit,2016(22):5131-5140.
[10]Peserico A,Germani A,Sanese P,et al.A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth[J].Journal of Cellular Physiology,2015,230(10):2447-2460.
[11]Zhang L,Jin Y,Yang H,et al.SMYD3 promotes epithelial ovarian cancer metastasis by down-regulating p53 protein stability and promoting p53 ubiquitination[J].Carcinogenesis,2019:bgz078.
[12]Mylonis I,Kourti M,Samiotaki M,et al.Mortalin-mediated and ERK-controlled targeting of HIF-1α to mitochondria confers resistance to apoptosis under hypoxia[J].J Cell Sci,2017,130(2):466-479.
[13]Jin H,Ji M,Chen L,et al.The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast[J].Journal of Experimental&Clinical Cancer Research,2016,35(1):42.
[14]Sun J,Che SL,Piao JJ,et al.Mortalin overexpression predicts poor prognosis in early stage of non-small cell lung cancer[J].Tumor Biology,2017,39(3):101042831769591.
[15]Ando K,Oki E,Zhao Y,et al.Mortalin is a prognostic factor of gastric cancer with normal p53 function[J].Gastric Cancer,2013,17(2):255-262.
[16]Xu M,Jin T,Chen L,et al.Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma[J].Gene,2019,69(6):63-71.
[17]Hu Y,Yang L,Yang Y,et al.Oncogenic role of mortalin contributes to ovarian tumorigenesis by activating the MAPK-ERK pathway[J].Journal of Cellular and Molecular Medicine,2016,20(11):2111-2121.
[18]Li S,Lv M,Qiu S,et al.NF-κB p65 promotes ovarian cancer cell proliferation and migration via regulating mortalin[J].J Cell Mol Med,2019,23(6):4338-4348.
[19]M?kinen N,Mehine M,Tolvanen J,et al.MED12,the Mediator Complex Subunit 12 Gene,Is Mutated at High Frequency in Uterine Leiomyomas[J].Science,2011,334(6053):252-255.
[20]Lim WK,Ong CK,Tan J,et al.Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma[J].Nature Genetics,2014,46(8):877-880.
[21]Barbieri CE,Baca SC,Lawrence MS,et al.Exome sequencing identifies recurrent SPOP,FOXA1 and MED12 mutations in prostate cancer[J].Nature Genetics,2012,44(6):685-689.
[22]Luo XL,Deng CC,Su XD,et al.Loss of MED12 Induces Tumor Dormancy in Human Epithelial Ovarian Cancer via Downregulation of EGFR[J].Cancer research,2018,78(13):3532-3543.
[23]Klepsch V,Hermann-Kleiter N.Beyond CTLA-4 and PD-1:Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy[J].Immunology letters,2016(178):31-36.
[24] Liu J,Li T.DDA1 is induced by NR2F6 in ovarian cancer and predicts poor survival outcome[J].European review for medical and pharmacological sciences,2017,21(6):1206-1213.
[25]Li H,Zhang W,Niu C,et al.Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway[J].International Journal of Cancer,2019,145(7):1921-1934.
[26]Gusev A,Lawrenson K,Lin X,et al.A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants[J].Nature Genetics,2019,51(5):815-823.
[27]Larsson VJ,Jafferali MH,Vijayaraghavan B,et al.Mitotic spindle assembly and γ-tubulin localisation depend on the integral nuclear membrane protein Samp1[J].Journal of Cell Science,2018,131(8):jcs211664.
[28]Zhou JX,Yang X,Ning S,et al.Identification of as the first cancer predisposition fusion gene specific to the population of European ancestry origin[J].Oncotarget,2017,8(31):50594-50607.
[29]Hanselmann S,Wolter P,Malkmus J.The microtubule-associated protein PRC1 is a potential therapeutic target for lung cancer[J].Oncotarget,2018,9(4):4985-4997.
[30]Landrum LM,Java J,Mathews CA,et al.Prognostic factors for stage Ⅲ epithelial ovarian cancer treated with intraperitoneal chemotherapy:a Gynecologic Oncology Group study[J].Gynecologic Oncology,2013,130(1):12-18.
[31]Spizzo G,Fong D,Wurm M,et al.EpCAM expression in primary tumour tissues and metastases:an immunohistochemical analysis[J].Journal of Clinical Pathology,2011,64(5):415-420.
[32]Lee S,Ahn HJ.Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA:Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo[J].Acta Biomater,2019(91):258-269.
[33]Song N,Liu B,Wu JL,et al.Prognostic value of HMGB3 expression in patients with non-small cell lung cancer[J].Tumor Biology,2013,34(5):2599-2603.
[34]Mukherjee A,Huynh V,Gaines K,et al.Targeting the High Mobility Group Box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin[J].Cancer Res,2019,79(13):3185-3191.
[35]Guo S,Wang Y,Gao Y,et al.Knockdown of High Mobility Group-Box 3 (HMGB3) Expression Inhibits Proliferation,Reduces Migration,and Affects Chemosensitivity in Gastric Cancer Cells[J].Medical Science Monitor,2016(22):3951-3960.
[36]Wang Y,Bao W,Liu Y,et al.miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1[J].Cell Death Dis,2018,9(5):447.
[37]Jin Y,Wei J,Xu S,et al.miR 210 3p regulates cell growth and affects cisplatin sensitivity in human ovarian cancer cells via targeting E2F3[J].Molecular Medicine Reports,2019.
[38]Liu J,Zhang X,Huang Y,et al.miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases[J].Oncology Letters,2019,17(2):1453-1460.
[39]Wu G,Cao L,Zhu J,et al.Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling[J].Clin Cancer Research,2019,25(3):1022-1035.
[40]Chung WM,Ho YP,Chang WC,et al.Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocar Hydrocarbon Receptor-ABCG2 Axis[J].Cancer (Basel),2019,11(4):E463.
[41] Sun NK,Huang SL,Chang PY,et al.Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response[J].Oncotarget,2014,5(23):11939-11956.
[42]Yeongseon B,Jeong-Won L, Soo CW, et al.CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer[J].Cancer Research,2018,78(21):6247-6256.
[43]Rebbeck TR,Mitra N,Wan F,et al.Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer[J].JAMA,2015,313(13):1347-1361.
[44]The Cancer Genome Atlas Research Network.Integrated genomic analysis of ovarian cancer[J].Nature,2011,474(7353):609-615.
[45]Ashour M.Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome[J].Cancer Management and Research,2019(11):6275-6284.
[46] 张国楠,黄建鸣.卵巢上皮癌分子分型和化疗耐药的再认识[J].中国妇产科临床杂志,2017,18(6):481-483.
[47]Huang JM,Zhang GN,Yu S,et al.Atractylenolide-I sensitizeshuman ovarian cancer cells to paclitaxel by blocking activationof TLR4/MyD88-dependent Pathway[J].Scientific Reports,2014(4):3840.
[48] Szajnik M,Szczepanski MJ,Czystowska M,et al.TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumorsurvival and chemoresistance in ovarian cancer[J].Oncogene,2009,28(49):4353-4363.
相似文献/References:
[1]袁东方,张刚刚.恶性肿瘤病历主要诊断选择思路分析[J].医学信息,2018,31(07):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
YUAN Dong-fang,ZHANG Gang-gang.Analysis of Main Diagnostic Options for Malignant Tumor Records[J].Journal of Medical Information,2018,31(18):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
[2]陶碧君,刘建德,王玉洲.LncRNA FOXD3-AS1在恶性肿瘤中的表达、功能及作用机制[J].医学信息,2022,35(10):51.[doi:10.3969/j.issn.1006-1959.2022.10.012]
TAO Bi-jun,LIU Jian-de,WANG Yu-zhou.Expression, Function and Mechanism of LncRNA FOXD3-AS1 in Malignant Tumors[J].Journal of Medical Information,2022,35(18):51.[doi:10.3969/j.issn.1006-1959.2022.10.012]
[3]张国锐,贾 林,赵 丹,等.老年维持血液透析患者恶性肿瘤发病的相关因素分析[J].医学信息,2022,35(10):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
ZHANG Guo-rui,JIA Lin,ZHAO Dan,et al.Analysis of Related Factors of Malignant Tumor in Elderly Maintenance Hemodialysis Patients[J].Journal of Medical Information,2022,35(18):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
[4]姜天奇,张洪亮.原发性肝癌的中西医治疗现状[J].医学信息,2019,32(13):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
JIANG Tian-qi,ZHANG Hong-liang.Current Status of Treatment of Primary Liver Cancer with Traditional Chinese Medicine and
Western Medicine[J].Journal of Medical Information,2019,32(18):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
[5]梁春玲,杨文珊.消化道恶性肿瘤的临床分析[J].医学信息,2019,32(18):124.[doi:10.3969/j.issn.1006-1959.2019.18.041]
LIANG Chun-ling,YANG Wen-shan.Clinical Analysis of Malignant Tumors of the Digestive Tract[J].Journal of Medical Information,2019,32(18):124.[doi:10.3969/j.issn.1006-1959.2019.18.041]
[6]陈云娥,李 璠,张子怡,等.营养支持治疗对终末期恶性肿瘤患者临床结局影响的Meta分析[J].医学信息,2019,32(19):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
CHEN Yun-e,LI Fan,ZHANG Zi-yi,et al.Meta-analysis of Effect of Nutritional Support Therapy on Clinical Outcome of Patients with Terminal-stage Malignant Tumor[J].Journal of Medical Information,2019,32(18):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
[7]杜鑫荣.超声造影在肝实质性肿块诊断及鉴别中的临床价值[J].医学信息,2019,32(19):176.[doi:10.3969/j.issn.1006-1959.2019.19.059]
DU Xin-rong.Clinical Value of Contrast-enhanced Ultrasonography in the Diagnosis and Differential Diagnosis of Liver Mass[J].Journal of Medical Information,2019,32(18):176.[doi:10.3969/j.issn.1006-1959.2019.19.059]
[8]谭金城,王羽丰,高 霞,等.上皮性卵巢癌中T淋巴细胞的浸润特征[J].医学信息,2022,35(15):164.[doi:10.3969/j.issn.1006-1959.2022.15.039]
TAN Jin-cheng,WANG Yu-feng,GAO Xia,et al.Infiltration Characteristics of T Lymphocytes in Epithelial Ovarian Cancer[J].Journal of Medical Information,2022,35(18):164.[doi:10.3969/j.issn.1006-1959.2022.15.039]
[9]易亭伍,邓窈窕,宿向东.恶性肿瘤患者及家属信息需求现状的多中心研究[J].医学信息,2019,32(22):72.[doi:10.3969/j.issn.1006-1959.2019.22.023]
YI Ting-wu,DENG Yao-tiao,SU Xiang-dong.Multi-center Study on the Status of Information Needs of Patients with Malignant Tumors and their Families[J].Journal of Medical Information,2019,32(18):72.[doi:10.3969/j.issn.1006-1959.2019.22.023]
[10]赵博志,赵国林,杨 敏,等.乳腺鳞状细胞癌的临床诊疗研究[J].医学信息,2020,33(03):46.[doi:10.3969/j.issn.1006-1959.2020.03.014]
ZHAO Bo-zhi,ZHAO Guo-lin,YANG Min,et al.Clinical Diagnosis and Treatment of Squamous Cell Carcinoma of the Breast[J].Journal of Medical Information,2020,33(18):46.[doi:10.3969/j.issn.1006-1959.2020.03.014]